866-997-4948(US-Canada Toll Free)

Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Technology and Pipeline Analysis, 2016

Published By :

DelveInsight

Published Date : Jan 2016

Category :

Therapeutic Area

No. of Pages : 224 Pages

DelveInsight Report,

Table of Contents 

1 Report Introduction

2 Executive Summary Snapshot

3 Executive Summary

4 Introduction

4.1. Chimeric antigen receptor (CAR) T-cells
4.2. History
4.3. CARs and Generations
4.4. Advantages of CAR-T cells
4.5. Adverse Events with CAR T-cell Therapy

5 CAR-T Cell Therapy-Analysis
5.1. CAR-T Collaboration Deals
5.1.1. CAR-T Cells Therapy Collaborations and Deal Year
5.1.2. Collaborations & Deal Value Trends
5.1.4. Companies collaborations for future developments
5.2. CAR-T Acquisitions Deals
5.2.1. CAR-T Cells Therapy Acquisitions Trends
5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants
5.3. New facilityfor the development of CAR-T cells
5.4. CAR-T Licensing Opportunities
5.5. Pipeline Scenario
5.5.1. Pipeline Products under Development-An Overview
5.5.2. Pipeline Products under Development by Company
5.5.3. CAR T-cells Therapeutic Areas & Companies
5.5.4. CAR-T cells Targeted Antigens
5.5.5. CAR-T Therapies-Clinical trials & Completion Year
5.5.6. CAR T-cell Technologies & Companies Involved
5.5.7. CAR-T Safety Switches & Company involved
5.5.8. Companies with Upcoming CAR-T Therapeutics

6 Pipeline Profiles

7 Upcoming Technologies Better than CARs

8 Market Drivers

9 Market Barriers

10 SWOT Analysis


11 Report Methodology

12 Consulting Services

List of Table


Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy – Company Collaborations and Deal Year, 2016
Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2016
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2016
Table 5: Companies CAR-T Investment for future developments, 2016
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2016
Table 7:Companies open for licensing and collaborations, 2016
Table 8:Number of Products under Development, 2016
Table 9: Number of Products under Development by Companies, 2016
Table 10: Number of Products under Development by Indication, 2016
Table 11:Number of Products Targeting CD19 Antigen, 2016
Table 12: Number of Products Targeting Other Antigens, 2016
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2016
Table 14: CAR T-cell Companies and Technologies, 2016

List of Chart


Figure 1: Companies Collaborations vs. Financial year, 2016
Figure 2: Number of Companies Collaborations, 2016
Figure 3: Collaborations and Deal Values (In million, $), 2016
Figure 4: Number of Products under Development, 2016
Figure 5: Number of Products under Development by Companies, 2016
Figure 6: Number of Products under Development by Indication, 2016
Figure 7: CAR-T cell Targeted Antigens (%),2016
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2016
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2016
Figure 10: CAR T-cell Companies and Technologies, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports